Akebia Therapeutics works to develop unique therapeutics that have the potential to set new standards of care for people living with kidney disease. Akebia is a fully integrated biopharmaceutical company with both an experienced nephrology-focused commercial team and a robust development organization. The company currently has two FDA-approved products, including Vafseo (vadadustat), an oral HIF-PH inhibitor approved for the treatment of anemia due to chronic kidney disease for patients on dialysis.